Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions: oncolytic viruses.

Liang You1, Biao He, Zhidong Xu

  • 1Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA.

Clinical Lung Cancer
|February 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Scoping Review of Malnutrition Risk Prediction Models in Cancer Patients.

Journal of clinical nursing·2026
Same author

<i>CFTR</i> gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles.

Molecular therapy. Nucleic acids·2026
Same author

T-Bet Modulates Plasmodium-Specific CD4<sup>+</sup> T Cell Differentiation and Anti-Malarial Immunity During Blood-Stage Infection.

Parasite immunology·2026
Same author

A dual-channel electron expressway triggers piezocatalytic ferroptosis-mitochondrial catastrophe cascade for anti-glioblastoma therapy.

Biomaterials·2026
Same author

Enhanced Energy Storage Performance in Mn-Doped BaTiO<sub>3</sub>-Based Epitaxial Thin Films.

ACS applied materials & interfaces·2026
Same author

Host macrophages/monocytes promote malaria transmission by modulating mosquito microbiota via SR-A-mediated phagocytosis.

Nature communications·2026
Same journal

Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer.

Clinical lung cancer·2026
Same journal

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Clinical lung cancer·2026
Same journal

Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report.

Clinical lung cancer·2026
Same journal

Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer.

Clinical lung cancer·2026
Same journal

Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis.

Clinical lung cancer·2026
Same journal

Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan.

Clinical lung cancer·2026
See all related articles

Oncolytic viruses are engineered to selectively destroy cancer cells, offering a promising new cancer treatment. This review highlights their potential, especially for lung cancer patients, and their synergy with traditional therapies.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Oncolytic viruses represent a novel therapeutic strategy for cancer treatment.
  • This approach utilizes viruses engineered to selectively infect and replicate within malignant tumor cells.
  • The goal is to achieve tumor destruction while sparing healthy tissues.

Purpose of the Study:

  • To review the potential of oncolytic viruses in cancer therapy.
  • To focus on oncolytic viruses that may benefit lung cancer patients.
  • To discuss the safety and efficacy demonstrated in clinical trials.

Main Methods:

  • Genetic engineering of viruses to target cancer-specific defects.
  • Development of viruses that replicate in tumor cells but not normal cells.

Related Experiment Videos

  • Review of existing clinical trial data and scientific literature.

    • Main Results:

    • Oncolytic viruses have demonstrated safety in clinical trials.
    • Encouraging results suggest efficacy in cancer treatment.
    • Evidence supports synergistic effects with standard cancer therapies.

    Conclusions:

    • Oncolytic viral therapy is a promising modality for cancer treatment.
    • Further research and clinical application are warranted, particularly for lung cancer.
    • The selective targeting mechanism offers a favorable safety profile.